Gilead’s Trodelvy May Have Safety Edge Due To Lack Of Concerning Lung Toxicity
Executives said there had been no cases of interstitial lung disease, while ILD – including fatal events – has become a potential problem for AstraZeneca/Daiichi Sankyo’s dato-DXd.
You may also be interested in...
Merck & Co's antibody-drug conjugates pact with Kelun is progressing well and the lead candidate of the pact, the TROP2-targeting candidate codenamed SKB264/MK-2870, has significantly improved progression-free survival in triple-negative breast cancer patients in a late-stage trial in China.
Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.
While the myelodysplastic syndrome trial news seems unlikely to read through to other programs, MDS may have been the drug’s biggest market.